Skip to main content

Table 2 Changes in lipid profile after pemafibrate treatment

From: Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study

Characteristic Weeks after pemafibrate treatment Pemafibrate treatment
Week − 8 Week − 4 Week 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 P* Baselinea Post-doseb P**
TG, median (IQR), mmol/L             
 Total 3.01 (2.50–4.08) 3.49 (2.60–5.43) 3.60 (2.69–5.44) 2.19 (1.55–2.47) 2.11 (1.47–2.42) 1.99 (1.42–2.87) 2.27 (1.72–2.81) 2.70 (2.01–3.59) 2.08 (1.75–2.69) < 0.0001 3.30 (2.63–4.76) 2.15 (1.72–2.44) < 0.0001
 Increased LDL-C group (group I) 3.25 (2.47–6.27) 4.52 (2.63–6.11) 4.03 (2.60–7.24) 2.22 (1.56–2.47) 2.07 (1.40–2.45) 2.00 (1.85–3.07) 2.27 (1.73–3.10) 2.74 (2.04–4.21) 1.90 (1.59–2.83) < 0.0001 3.71 (2.62–6.69) 2.11 (1.61–2.57) < 0.0001
 No LDL-C increase group (group NI) 2.90 (2.51–3.77) 3.01 (2.31–4.03) 3.26 (2.77–4.08) 2.10 (1.50–2.54) 2.17 (1.68–2.42) 1.70 (1.26–2.50) 2.22 (1.64–2.69) 2.57 (1.82–3.10) 2.24 (1.82–2.69) < 0.0001 3.25 (2.64–3.80) 2.20 (1.92–2.42) < 0.0001
P*** 0.3946 0.0683 0.1178 0.5890 0.6870 0.3952 0.7561 0.5934 0.7648   0.1495 0.6241  
LDL-C, median (IQR), mmol/L             
 Total 3.10 (2.61–3.59) 3.00 (2.23–3.47) 3.08 (2.30–3.59) 2.84 (2.33–3.41) 3.15 (2.64–3.72) 2.72 (2.15–3.36) 3.13 (2.59–3.52) 2.72 (1.97–3.65) 2.92 (2.59–3.57) 0.8679 3.10 (2.40–3.59) 3.19 (2.74–3.70) 0.0170
 Increased LDL-C group (group I) 2.66 (2.02–3.21) 2.66 (1.91–3.52) 2.51 (1.71–3.13) 3.21 (2.25–3.49) 3.28 (2.72–4.19) 3.10 (1.91–3.67) 3.00 (2.46–3.75) 3.31 (1.86–3.96) 3.39 (2.87–4.09) 0.0483 2.53 (1.96–3.26) 3.31 (2.77–4.11) < 0.0001
 No LDL-C increase group (group NI) 3.26 (2.92–3.78) 3.26 (2.82–3.47) 3.52 (2.87–3.75) 2.69 (2.33–2.84) 2.92 (2.64–3.41) 2.59 (2.22–3.05) 3.15 (2.72–3.44) 2.64 (2.28–3.21) 2.74 (2.56–3.10) 0.0157 3.36 (3.05–3.72) 3.03 (2.66–3.44) 0.0022
P*** 0.0024 0.0759 0.0008 0.4414 0.1583 0.4616 0.7042 0.8415 0.0603   0.0009 0.2418  
HDL-C, median (IQR), mmol/L             
 Total 1.27 (1.01–1.45) 1.22 (0.98–1.42) 1.22 (1.01–1.42) 1.22 (1.09–1.45) 1.37 (1.16–1.53) 1.42 (1.14–1.55) 1.29 (1.06–1.47) 1.22 (0.98–1.55) 1.27 (1.01–1.55) 0.5147 1.22 (1.03–1.40) 1.32 (1.14–1.53) < 0.0001
 Increased LDL-C group (group I) 1.16 (0.93–1.37) 1.22 (0.96–1.32) 1.14 (0.85–1.32) 1.14 (1.06–1.27) 1.37 (1.06–1.50) 1.37 (1.22–1.45) 1.22 (0.91–1.50) 1.19 (0.96–1.55) 1.27 (1.03–1.66) 0.2396 1.16 (0.93–1.29) 1.29 (1.09–1.53) < 0.0001
 No LDL-C increase group (group NI) 1.29 (1.14–1.55) 1.29 (1.03–1.58) 1.32 (1.06–1.50) 1.42 (1.11–1.47) 1.37 (1.16–1.60) 1.45 (0.98–1.71) 1.34 (1.11–1.47) 1.24 (1.09–1.55) 1.29 (1.09–1.53) 0.9936 1.32 (1.06–1.50) 1.34 (1.14–1.55) 0.0258
P*** 0.0465 0.1829 0.0194 0.1589 0.5368 0.9096 0.6165 0.8413 1.0000   0.0267 0.5090  
Non − HDL-C, median (IQR), mmol/L            
 Total 4.71 (4.37–5.15) 4.55 (4.34–5.72) 4.71 (4.27–5.43) 3.52 (3.10–4.37) 4.27 (3.52–4.78) 3.80 (3.10–4.34) 4.14 (3.72–4.45) 4.03 (3.59–4.47) 3.96 (3.62–4.31) < 0.0001 4.84 (4.32–5.28) 4.14 (3.52–4.58) < 0.0001
 Increased LDL-C group (group I) 4.73 (4.09–5.46) 4.65 (3.98–6.52) 4.55 (4.01–5.33) 3.85 (3.26–4.76) 4.45 (3.52–4.99) 4.16 (3.28–4.53) 3.98 (3.67–4.55) 3.98 (3.57–4.78) 4.06 (3.72–4.99) 0.1581 4.86 (4.03–5.35) 4.24 (3.41–4.84) 0.0063
 No LDL-C increase group (group NI) 4.71 (4.40–5.04) 4.55 (4.34–5.59) 4.84 (4.40–5.66) 3.34 (2.82–3.70) 4.19 (3.39–4.63) 3.62 (2.84–3.98) 4.22 (3.75–4.42) 4.09 (3.08–4.34) 3.75 (3.52–4.11) < 0.0001 4.76 (4.45–5.20) 4.06 (3.57–4.50) < 0.0001
P*** 0.7853 0.9613 0.2362 0.2466 0.2472 0.3356 0.6662 0.8415 0.1653   0.6834 0.5220  
  1. P < 0.05 was considered statistically significant. aMean value of 3 measurements before pemafibrate; bMean value of 6 measurements after pemafibrate. *, Statistical analysis was done using the Kruskal-Wallis test. **, Statistical analysis was done using Wilcoxon signed-rank test. ***, Statistical analysis between groups I and NI was done using the Mann-Whitney U test. IQR Inter-quartile range, TG Triglycerides, LDL-C Low density lipoprotein cholesterol, HDL-C High density lipoprotein cholesterol